TSHA - Taysha Gene Therapies, Inc.

QQQ $ 604.79 $ 3.94 (0.66 %)

DIA $ 462.00 $ 2.22 (0.48 %)

SPY $ 665.27 $ 3.75 (0.57 %)

TLT $ 91.09 $ -0.14 (-0.15 %)

GLD $ 391.11 $ -7.46 (-1.88 %)

Previous Close

$ 4.72

Open

$ 4.91

Bid

$ 4.65 x 50

Ask

$ 4.70 x 1,025

Day's Range

$ 4.43 - $ 4.92

52 Week Range

$ 1.05 - $ 5.51

Volume

9,102,477

Average Volume

Market Cap

1.29B

Beta (5Y Monthly)

$ 1.73

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-15-2025	03-31-2025	10-Q
3	02-26-2025	12-31-2024	10-K
4	11-13-2024	09-30-2024	10-Q
5	08-12-2024	06-30-2024	10-Q
6	05-14-2024	03-31-2024	10-Q
7	03-19-2024	12-31-2023	10-K
8	11-14-2023	09-30-2023	10-Q
9	08-14-2023	06-30-2023	10-Q
10	05-11-2023	03-31-2023	10-Q
11	03-28-2023	12-31-2022	10-K
12	11-08-2022	09-30-2022	10-Q
13	08-11-2022	06-30-2022	10-Q
14	05-16-2022	03-31-2022	10-Q
15	03-31-2022	12-31-2021	10-K
16	11-10-2021	09-30-2021	10-Q
17	08-16-2021	06-30-2021	10-Q
18	05-11-2021	03-31-2021	10-Q
19	03-03-2021	12-31-2020	10-K
20	11-12-2020	09-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

why-is-taysha-gene-therapies-stock-falling-friday

Why Is Taysha Gene Therapies Stock Falling...
10/17/2025 16:44:00

Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for p...

Needham Reiterates Buy on Taysha Gene Ther...
10/17/2025 10:37:03

Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $10 price target.

Taysha Gene Therapies Regains Full Rights ...
10/16/2025 20:06:34

DALLAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage b...

Taysha Gene Announces Results From Supplem...
10/09/2025 12:04:56

Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥...

Demystifying Taysha Gene Therapies: Insigh...
10/02/2025 18:01:35

Baird Maintains Outperform on Taysha Gene ...
10/02/2025 17:52:42

Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $...

12 Health Care Stocks Moving In Thursday's...
10/02/2025 17:06:31

taysha-gene-therapies-canaan-ondas-holdings-and-other-big-stocks-moving-higher-on-thursday

Taysha Gene Therapies, Canaan, Ondas Holdi...
10/02/2025 16:29:57

U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.

Needham Maintains Buy on Taysha Gene Thera...
10/02/2025 14:51:58

Needham analyst Gil Blum maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $8 to $10.

top-2-health-care-stocks-that-may-keep-you-up-at-night-this-month

Top 2 Health Care Stocks That May Keep You...
10/02/2025 13:06:22

FDA Grants Breakthrough Therapy Designatio...
10/02/2025 12:03:48

Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from a...

What's Driving the Market Sentiment Around...
09/18/2025 17:00:40

Is Taysha Gene Therapies Gaining or Losing...
08/25/2025 15:01:04

A Glimpse Into The Expert Outlook On Taysh...
08/13/2025 13:00:41

Wells Fargo Maintains Overweight on Taysha...
08/13/2025 12:53:24

Wells Fargo analyst Yanan Zhu maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and raises the price target fr...

Canaccord Genuity Maintains Buy on Taysha ...
08/13/2025 10:50:31

Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target ...

Chardan Capital Maintains Buy on Taysha Ge...
08/12/2025 21:19:51

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target...

Taysha Gene Therapies Q2 EPS $(0.09) Misse...
08/12/2025 12:01:45

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate ...

Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

What's Next: Taysha Gene Therapies's Earni...
08/11/2025 16:02:20